SCHEMBL13628910

SCHEMBL13628910

CCCCOc1ccc(CC[C@](C)(CO)NC(=O)OC(C)(C)C)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 7/20 0.50
S1PR4 O95977 5/20 0.50
S1PR3 Q99500 5/20 0.50
S1PR5 Q9H228 4/20 0.50
KDM4E B2RXH2 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2D6 P10635 1/20 0.45
PDE4A P27815 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
HIF1A Q16665 1/20 0.45
HDAC10 Q969S8 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
ITGB3 P05106 1/20 0.43
ITGA2B P08514 1/20 0.43
ALDH1A1 P00352 1/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA9 Q16790 1/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL296830 0.98 S1PR1 (0.54) S1PR1S1PR4S1PR3S1PR5KDM4E
SCHEMBL12721394 0.96 S1PR1 (0.56) S1PR1S1PR4S1PR3S1PR5SMN1; SMN2
SCHEMBL1624956 0.96 S1PR1 (0.56) S1PR1S1PR4S1PR3S1PR5SMN1; SMN2
SCHEMBL688475 0.91 PPARG (0.47) S1PR1S1PR4S1PR3S1PR5ITGB3
SCHEMBL4816575 0.90 FFAR1 (0.51) S1PR1S1PR3
SCHEMBL3741361 0.88 S1PR1 (0.44) S1PR1S1PR4S1PR3S1PR5
SCHEMBL6258194 0.87 S1PR1 (0.53) S1PR1S1PR4S1PR3S1PR5KDM4E
SCHEMBL6241196 0.86 S1PR1 (0.55) S1PR1S1PR4S1PR3S1PR5SMN1; SMN2
SCHEMBL6257363 0.86 S1PR1 (0.55) S1PR1S1PR4S1PR3S1PR5SMN1; SMN2
SCHEMBL6236920 0.86 S1PR1 (0.55) S1PR1S1PR4S1PR3S1PR5SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612238-B2 Such as (R)-2-amino-2-methyl-4-[4-(4,4,5,5,5-pentafluoro-pentyloxy)-phenyl]-butan-1-ol hydrochloride for treatment of disorders or diseases mediated by lymphocytes, and for treating acute or chronic transplant rejection or T-cell-mediated inflammatory or autoimmune diseases NOVARTIS AG (CH) 2009-11-03 US disclosed